These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 11781194)

  • 1. Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors. I. Phase I-II clinical trials of recombinant human interleukin-1 beta as a leukopoiesis stimulator in cancer patients receiving combination chemotherapy.
    Gershanovich ML; Filatova LV; Ketlinsky SA; Simbirtsev AS
    Eur Cytokine Netw; 2001; 12(4):664-70. PubMed ID: 11781194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors. II. Phase II study of the protective effect of recombinant human interleukin-1 beta on myelodepression induced by chemotherapy in cancer patients.
    Gershanovich ML; Filatova LV; Ketlinsky SA; Simbirtsev AS
    Eur Cytokine Netw; 2001; 12(4):671-5. PubMed ID: 11781195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Betaleukin (human recombinant interleukin-1beta) for the prevention and correction of toxic leukopenia in chemotherapy of malignant neoplasms].
    Gershanovich ML; Filatova LV; Ketlinskiĭ SA; Simbirtsev AS
    Vopr Onkol; 1998; 44(2):181-6. PubMed ID: 9615823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Stimulating and protective effect of recombinant interleukin-1-beta (beta-leukin) on leukopoiesis in chemotherapy of malignant tumors].
    Gershanovich ML; Ketlinskiĭ SA; Filatova LV; Danova LA; Korolenko VO; Simbirtsev AS
    Vopr Onkol; 1996; 42(6):13-8. PubMed ID: 9123895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The leuko-stimulating and protective action of human recombinant interleukin-1 beta (betaleukin) in the chemotherapy of malignant tumors].
    Filatova LV; Gershanovich ML; Ketlinskiĭ SA; Simbirtsev AS
    Vopr Onkol; 2000; 46(3):278-84. PubMed ID: 10976272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
    Mantovani G; Macciò A; Madeddu C; Mulas C; Massa E; Astara G; Ferreli L; Mudu MC; Gramignano G; Murgia V; Lusso MR; Mocci M; Cardia A; Mura L
    Oncol Rep; 2002; 9(4):887-96. PubMed ID: 12066227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
    Cripe LD; Rader K; Tallman MS; Gordon MS; Paietta E; Bennett J; Neuberg D; Litzow MR; O'brien TE; Rowe JM
    Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
    J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of recombinant human interleukin-1 beta (rhIL-1 beta) in patients with bone marrow failure.
    Nemunaitis J; Ross M; Meisenberg B; O'Reilly R; Lilleby K; Buckner CD; Appelbaum FR; Buhles W; Singer J; Peters WP
    Bone Marrow Transplant; 1994 Oct; 14(4):583-8. PubMed ID: 7858532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
    Cairo MS; Davenport V; Bessmertny O; Goldman SC; Berg SL; Kreissman SG; Laver J; Shen V; Secola R; van de Ven C; Reaman GH
    Br J Haematol; 2005 Jan; 128(1):49-58. PubMed ID: 15606549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
    Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Phase II clinical trial on China manufactured recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapy-induced thrombocytopenia].
    Wang XY; Feng FY; Song ST; Wang HQ; Zhang MH; Liu J; Liu XY; Xu LG; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):373-6. PubMed ID: 16117903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
    Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS
    Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
    Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose carboplatin, cyclophosphamide, etoposide with hematological growth factors, without stem cell support in patients with advanced cancer.
    Recchia F; De Fillipis S; Piccinini M; Rea S
    Anticancer Res; 2003; 23(5b):4141-7. PubMed ID: 14666615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Centrally administered interleukin-1 beta sensitizes to the central pressor action of angiotensin II.
    Ufnal M; Dudek M; Zera T; Szczepańska-Sadowska E
    Brain Res; 2006 Jul; 1100(1):64-72. PubMed ID: 16765325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia].
    Lei W; Liang J; Chen WG; Ma XZ; Xu M; Du LL
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):542-4. PubMed ID: 17147124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
    Lenzi R; Rosenblum M; Verschraegen C; Kudelka AP; Kavanagh JJ; Hicks ME; Lang EA; Nash MA; Levy LB; Garcia ME; Platsoucas CD; Abbruzzese JL; Freedman RS
    Clin Cancer Res; 2002 Dec; 8(12):3686-95. PubMed ID: 12473577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
    Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.